ELDN logo

ELEDON PHARMACEUTICALS INC

ELDNNASDAQ
🏆 #3708 by market capUS Equity
$2.52▼ $0.13 (−5.09%)
Market closed · at close
🔔
Track ELDN
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 5.1%
7d▼ 7.9%
14d▼ 5.8%
30d▼ 15.0%
ytd▲ 67.1%
1y▼ 3.3%
🏦Market Cap
$194M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
60
Fair

Trading Snapshot

Day Range
$2.48 – $2.54
52-Week Range
$1.35 – $4.60
Volume
$2.95B
Avg Volume
$3.35B
Shares Outstanding
77.2M
Next Earnings
Oct 19, 2026

Fundamentals Snapshot

Annual Revenue
$19M
Last Q Revenue
$5M
P/E Ratio
-2.7
P/S Ratio
0.0x
EPS (TTM)
$-0.87
Dividend Yield
0.00%
Dilution (1yr)
+26.2%

Why Investors Own ELDN

  • ✓High-growth profile — revenue up +22.0% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 41% gross margin and 10% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ELDN logo

ELEDON PHARMACEUTICALS INC

ELDN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$83M▲ +18.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$62M▲ +31.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
75.4M▲ +26.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$22M▲ +$3M YoY
StockOtter · stockotter.space

About ELEDON PHARMACEUTICALS INC

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Price Target

ⓘ
Average Target
$2.72
▲ +8.1% Upside
High Target$3.29
Low Target$2.31
Based on 27 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

ELEDON PHARMACEUTICALS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift ELDN price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

ELEDON PHARMACEUTICALS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.